Updates are available Correction dated 2023-12-18
Click to view Correction: https://doi.org/10.1038/s41598-023-49214-x
Updates are available Correction dated 2024-02-07
Click to view Correction: https://doi.org/10.1038/s41598-024-53751-4
-
Authors
Erasmus, M. Frank
Ferrara, Fortunato
D’Angelo, Sara
Spector, Laura
Leal-Lopes, Camila
Teixeira, André A.
Sørensen, Jesper
Nagpal, Suhani
Perea-Schmittle, Kathryn
Choudhary, Alok
Honnen, William
Calianese, David
Antonio Rodriguez Carnero, Luis
Cocklin, Simon
Greiff, Victor
Pinter, Abraham
Bradbury, Andrew R. M.
- License Information
-
More Information
Article History
Received: 9 August 2023
Accepted: 20 October 2023
First Online: 26 October 2023
Change Date: 7 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-024-53751-4
Change Date: 18 December 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41598-023-49214-x
Competing interests
: FF, MFE, SD, LS, LC, SC, and ARMB are employees of Specifica, LLC, a Q2 Solutions company. SN and JS are employees at OpenEye, Cadence Molecular Sciences. All other authors declare no competing interests. AAT, MFE and ARMB are listed as inventors: 10,954,508 application status: granted; 17/208,877 application status: allowed; 17/163,170 application status: pending; number EP 19834484.0; application status: pending; Number JP 2021-523556; application status: pending; Number CA 3106115 application status: pending. The antibodies described in the manuscript are covered by the following patent application: patent applicant: Specifica LLC, a Q2 Solutions Company, inventor names: ARMB, FF, MFE, number 63/211432, application status: provisional.
